Physician profile
Laura B Acker
NPI 1679123764
$1,903.54
in general payments reported to CMS, 2019-2025
14 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $776 · 2022: $68.64 · 2023: $521 · 2024: $328 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.32 |
| Education | $182.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $635.00 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $264.68 | 2021 | |
| Janssen Biotech, INC. | $197.15 | 2022-2025 | Darzalex, Tecvayli, Carvykti |
| Lilly USA, LLC | $149.86 | 2021 | |
| Kite Pharma, INC. | $124.99 | 2024 | |
| Amgen INC. | $124.92 | 2021 | |
| Incyte Corporation | $121.08 | 2024 | Jakafi |
| Novo Nordisk INC | $80.87 | 2021 | |
| Glaxosmithkline, LLC. | $55.34 | 2021 | |
| Novartis Pharmaceuticals Corporation | $46.13 | 2021 | |
| Astellas Pharma US INC | $30.35 | 2025 | Cresemba |
| Amarin Pharma, INC. | $28.73 | 2021 | |
| Genzyme Corporation | $24.53 | 2023 | |
| Merck Sharp & Dohme LLC | $19.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Acker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.